Navigation Links
Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
Date:1/21/2009

ALLEGAN, Mich., Jan. 21 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2009 on Tuesday, February 3, 2009 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman and Chief Executive Officer.

The conference call will be available live via webcast to interested parties on the Perrigo website http://www.perrigo.com or by phone 877-248- 9413, International 973-582-2737 and reference ID# 80886866. A taped replay of the call will be available beginning at approximately 2:00 p.m. (ET) Tuesday, February 3, until midnight Friday, February 13, 2009. To listen to the replay, call 800-642-1687, International 706-645-9291, access code 80886866.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).


'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
2. Perrigo Announces FDA Final Approval for Ibuprofen PM
3. Perrigo Settles Desloratadine Patent Litigation
4. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
5. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
6. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
7. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
8. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
9. Perrigo Company Announces Appointment of New Board Member
10. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
11. Perrigo Announces Approval for Rx Cetirizine Syrup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... ... 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD ... a benign bony lump located on the forehead usually attributed to a facial fracture. ... and pain. Dr. Shah has discovered an approach that is minimally invasive. He is ...
(Date:4/21/2017)... ... ... Dudnyk has announced the launch of its new brand identity, called The ... specialty and orphan brands can only be achieved when the needs and beliefs of ... at the heart of a true partnership between our agency and our clients to ...
(Date:4/21/2017)... ... ... The Hong Kong Polytechnic University (PolyU) launched today the University Research Facility ... Hong Kong to support teaching, learning and research. It is also the largest research ... Hong Kong. , With an area of 620 square metres and more than ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway Management, the medical device ... highly regarded and well renowned Asian distributor, Discovery Sleep. The agreement ... Pillow Mask, and will stabilize and strengthen Airway’s presence with a dedicated, reputable ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of ... Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, ... ... at US$ 7,167.6 Mn in 2015, and is expected to ... of 5.6% from 2016 to 2024. The ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: